Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]

Abstract

Simmi Wiggins,1,* Noah A Levit2,* 1Sanofi, 410 Thames Valley Park Dr, Reading, RG6 1PT, UK; 2Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA*These authors contributed equally to this workCorrespondence: Simmi Wiggins, Sanofi, 410 Thames Valley Park Dr, Reading, RG6 1PT, UK, Tel [phone], Fax [phone], Email [email protected]

Keywords

• dupilumab
• prurigo nodularis
• skin infections